OA 中文
Big news: Inspiring! Class 1 new drug - recombinant staphylococcus aureus vaccine (Escherichia coli) finished phase I clinical trial
2018.01.03

Recently, the Recombinant Staphylococcus aureus Vaccine (Escherichia coli) co-developed by Olymvax Biopharmaceuticals Inc. and Third Military Medical University of China People's Liberation Army have received the phase I clinical trial summary report issued by the Jiangsu Provincial Center for Disease Control and Prevention.

This report concluded that: for the Recombinant Staphylococcus aureus Vaccine (Escherichia coli), its safety is clinically acceptable. The immunogenicity of the vaccine is good, and the specific humoral and cellular immune responses can be rapidly induced until the 7th day after vaccination, and peaked on days 14-21. This the report for the first super-bacterial vaccine in China, marking another step toward its industrialization.

On February 27, 2017, WHO published for the first time a list of 12 "superbugs" posing the greatest threat to human health and hoped that this list would push governments to introduce policies to encourage the development of new drugs. Staphylococcus aureus co-developed by Olymvax ranked as "a high priority." At present, major biopharmaceutical companies such as Merck, Pfizer and GSK are stepping up vaccine research for "superbugs", but no product has been successfully developed yet.

111

The referred vaccine of Olymvax was designed with advanced reverse screening technology, 5 protective antigen components were selected, via recombinant E. coli expression, the vaccine was produced. This vaccine targeted people in high-risk of Staphylococcus aureus infections, including: surgical patients, the elderly, the infants and the weak. Staphylococcus aureus is the most common pathogen in hoapital that may cause renal cortical abscesses, endocarditis, toxic shock syndromes, severe lung infections and food poisoning. Therefore, the developing of this vaccine has significant importance.

This vaccine are expected to finish clinical trials at the end of the "Thirteenth Five-year Plan" period of China and will be launched in the market. It will create tremendous economic benefits while vigorously promoting national health.